Table 3.

Summary of adverse events by severity

Adverse events	Any grade	Grade 1	Grade 2	Grade 3	Grade 4	Treatment-related grade ≥ 3
Non-hematological toxicity
Increased AST level	30	23	4	3	0	2
Increased ALT level	27	23	3	1	0	1
Abnormal ECG	22	22	0	0	0	0
Vomiting	22	1	19	1	0	1
Nausea	18	15	3	0	0	0
Fatigue	18	16	2	0	0	0
Numbness	17	16	1	0	0	0
Gingivitis	15	10	5	0	0	0
Hyponatremia	15	14	0	1	0	0
Hypoproteinemia	15	10	5	0	0	0
Increased total bilirubin	13	5	5	3	0	0
Rash	11	3	6	2	0	2
Insomnia	11	5	6	0	-	0
Poor appetite	11	6	5	0	0	0
Abnormal pain	10	3	7	0	0	0
Hypopotassemia	10	8	0	2	0	0
Fever	9	2	7	0	0	0
Hoarse voice	9	9	0	0	0	0
Constipation	9	1	8	0	0	0
Epistaxis	9	9	0	0	0	0
Increases creatinine level	9	7	2	0	0	0
Hypothyroidism	8	4	4	0	0	0
Hypertension	8	0	8	0	0	0
Leg soreness	7	7	0	0	0	0
Weight loss	7	6	1	0	0	0
Headache	6	6	0	0	0	0
Hand-foot syndrome	6	4	2	0	0	0
Hyperthyroidism	5	2	3	0	0	0
Diarrhea	5	0	5	0	0	0
Cough	5	4	1	0	0	0
Tinnitus	4	4	0	0	0	0
Proteinuria	4	1	1	2	-	2
Adrenocortical insufficiency	2	1	0	1	0	1
Myocarditis	1	0	1	0	0	0
Interstitial pneumonia	1	0	0	1	0	1
Cholecystitis	1	0	1	0	0	0
Upper gastrointestinal hemorrhage	1	0	0	1	0	1
Sepsis	1	0	0	1	0	0
Gastrointestinal fistula	1	0	0	1	0	0
Hematological toxicity
Thrombocytopenia	24	16	7	1	0	1
Anemic	24	16	6	2	0	1
Neutropenia	23	7	4	9	3	12
Leukocytopenia	22	3	12	7	0	7

Data are reported as no. Only AEs occurring during treatment or within 30 days of the last study medication are reported. A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category for that treatment. A patient with multiple AEs is counted only once in the total row

AEs adverse events